9月24日 - ** 疗法开发商Immuneering IMRX.O的股票在延时交易中上涨38.5%至12.78美元
** 公司称其疗法IMM-1-104在胰腺癌患者为期9个月的中期试验中与吉西他滨联合治疗的总体反应率达到86%。
** 该公司预计将在第四季度获得监管部门对试验计划的反馈意见。
** 另外，IMRX称赛诺菲SASY.PA已同意在私募交易中购买其2500万美元的股票，预计该交易将与发行同时完成
** 公司打算将净收益用于推进候选产品的临床前和临床开发。
** 截至上次收盘，公司股价在过去一年中上涨了两倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.